Case report
Open access
Jul 2026
Thyroid eye disease with teprotumumab-related hyperglycemia associated with increased growth hormone secretion
Abstract Teprotumumab, an insulin-like growth factor-1 (IGF-1) receptor antibody, has been approved for thyroid eye disease (TED) treatment. However, teprotumumab is associated with adverse events such as hyperglycemia, and the underlying mechanisms of teprotumumab-related hyperglycemia remain unclear. We report a case...
Ken Sugawa, Yuji Hataya, Kimiaki Murabe et al.
· JCEM Case Reports · 1 citation